Technical and Clinical Validation of the WPM-SEMG Prototype

The study consists of two parts:

• the first part concerns the technical validation of the prototype. It will enrol 10 healthy volunteers (Technical Validation Group).
• the second part concerns the clinical validation of the prototype in comparison with the gold standard, that is the needle-EMG. It will enrol 50 healthy volunteers (Clinical Validation Group), including also the 10 subjects of the Technical Validation Group, and 20 patients

Measurements will be done on 4 muscles with the WPM-SEMG device prototype using a rigid electrode matrix. For each muscle, the participant will execute some spontaneous motor activities and measurements will be taken on the muscle under tension (low, medium, and high) for a total of 12 measurements. Measurements will be repeated two times after a pause for a total of 24 acquisitions. For the group with myopathies an additional fifth muscle, not foreseen by the protocol, can be done if considered the clinical most affected muscle followingthe neurological examination.

A control intervention is done on the same subjects and consists in a needle-EMG which will be applied as for routine clinical practice on the same muscles used for the WPM-SEMG device prototype. Measurements will be taken for each muscles as for the rigid matrix.

Eligibility criteria for healthy volunteers

• Inclusion Criteria

• Healthy volunteers
• Female or male
• 18 years or older
• Preserved cognitive capacity
• Ability to understand the study
• Willingness to complete all the study assessments
• No chronic or concomitant use of medications or treatment
• Written informed consent
• Exclusion Criteria

• Skin lesions in the area below the electrode
• Allergy to metal alloys
• History of skin disease
• Pregnancy
• Lactation
• Known causes of neuromuscular disease
• Inability to follow the procedures of the study

Eligibility criteria for patients

• Inclusion Criteria

• Patients of the Neurocentro della Svizzera Italiana with diagnosis of myopathy or neuropathy that requires a needle-EMG electrophysiological testing as standard clinical management of the disease
• Female or male
• 18 years or older
• Preserved cognitive capacity
• Ability to understand the study
• Willingness to complete all the study assessments
• No chronic or concomitant use of medications or treatment that may influence the measure in the opinion of the investigator (muscle relaxant such as baclofen, statin, benzodiazepine).
• Written informed consent
• Exclusion Criteria

• Skin lesions in the area below the electrode
• Allergy to metal alloys
• History of skin disease
• Cognitive and/or psychiatric disorders
• Pregnancy
• Lactation
• Neuromuscular disease other than myopathy and neuropathy
• Inability to follow the procedures of the study